Antibiotics Market is expected to grow at a CAGR of 4.15%

Visiongain published a new report titled antibiotics 2023-2033 It includes antibiotic profiles and forecasts Market Segment by Mechanism of Action (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others), Market segment by drug class (cephalosporin, penicillin, fluoroquinolone, macrolide, carbapenem, aminoglycoside, sulfonamide, 7-ACA, others), market segment by gender (male, female), market segment by age group (0-14 years, 15-54 years, 55 years and older), market segment by route of administration (oral, intravenous, other), plus analysis of the impact of COVID-19 and analysis of recovery patterns (V-shaped, W-shaped, ” U’-shaped, “L”-shaped), profiles of leading companies, region and country.

The antibiotics market was valued at USD 44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

Expansion by major players to offer competitive advantage

Acquisitions are used by companies in the antibiotic industry as a key strategy to expand their capabilities, and this is one of the strategies used by these companies. This enables the continuous acquisition of resources that is necessary to maintain our competitive edge. Continuous growth of an organization’s existing resources and talent, in addition to the acquisition of new ones, is essential for firms to maintain or regain their competitive edge. New skills can be acquired through internal growth of an organization as well as through mergers, collaborations and acquisitions. According to the results of an analysis carried out by Visiongain for this study, the majority of players use the acquisition strategy as a typical technique for building or acquiring abilities. While some businesses buy other businesses to expand into new geographic markets, others do so to increase the variety of goods and services they provide to customers. The search by firms for regions with reduced production costs can also lead to acquisitions. Acquisitions may also occur as a result of governments requiring multinational companies to have a local presence and obliging those companies to either start a new local business or acquire an existing one. The second option is the one that the majority of antibiotic companies have decided to go with. Last but not least, mergers and acquisitions allow businesses to move quickly, allowing them to enter new markets with their existing customers, reduce the bureaucratic burdens associated with starting a company, and acquire technology that would otherwise require much development time and effort. Companies in the antibiotic business choose to expand their capabilities in this way for a variety of reasons, some of the most important of which are listed above.

Download an exclusive sample report

How has COVID-19 significantly impacted the antibiotics market?

The COVID-19 pandemic has had a significant impact on antibiotic production. Increased demand for antibiotics to treat patients with COVID-19 has led to shortages of some drugs as manufacturers prioritize production of these drugs. In addition, many clinical trials for new antibiotics have been delayed or halted due to disruptions caused by the pandemic. On the other hand, the increased demand for antibiotics has also led to an increase in the prices of some drugs. This makes them less accessible to patients and health systems in low- and middle-income countries (LMIC). In addition, the pandemic has also highlighted the importance of antibiotic resistance, which has been a growing concern in recent years. Overall, the COVID-19 pandemic has focused attention on the importance of the antibiotic industry and the need for effective drugs to fight bacterial infections, but it has also highlighted the challenges of ensuring access to these drugs for all patients and the need to reduce the development of antibiotic resistance.

How will this report benefit you?

Visiongain’s 385-page report provides 144 tables and 223 charts/graphs. Our new research is suitable for anyone who needs commercial, in-depth analysis of the Antibiotics market along with detailed segment analysis of the market. Our new study will help you assess the overall global and regional antibiotics market. Get financial analysis of the overall market and various segments including mechanism of action, drug class, gender, age group, route of administration and gain higher market share. We believe there is great opportunity in this fast-growing antibiotic market. See how to leverage existing and upcoming opportunities in this market to reap revenue benefits in the near future. Additionally, the report will help you improve strategic decision-making, enabling you to outline growth strategies, reinforce analysis of other market players, and maximize company performance.

What are the current market drivers?

Rising burden of infectious diseases to drive market growth

Increasing cases of bacterial infections will drive the demand for antibiotics, which in turn will favor the antibiotic market. During the forecast period, increasing incidence of tuberculosis, malaria, pneumonia, bacterial skin infections, HIV/AIDS, urinary tract infections (UTI) and others would boost the healthy development of the market. According to the Centers for Disease Control and Prevention (CDC), there are about 15.5 million hospital visits and 3.7 million emergency room visits annually for infectious and parasitic diseases. There are still developing new sources of infection such as Severe Acute Respiratory Syndrome (SARS), Zika virus and Corona virus are a few examples. An infection occurs when another organism enters the host’s body and causes disease. The types that cause infections are very complex and can include things like viruses, bacteria, fungi and parasites. The infection can be contracted from the host in several different ways, such as directly from an infected person, through contaminated food or drink, and also from an insect bite. Very often, bacterial infections are treated with antibiotics. Antibiotics are drugs that affect the growth of bacteria. They can either inhibit the replication of bacteria or kill them completely. There are different types of antibiotics. Those prescribed will depend on the type of bacteria causing the infection. In addition, the misuse of antibiotics has caused many bacteria to develop resistance against the specific antibiotics.

Aging population offers lucrative growth prospects for antibiotic market players

Adults over the age of 65 are considered one of the most vulnerable segments of the population. The world is approaching a demographic tipping point. Since the dawn of mankind, little children have outnumbered their parents. Within five years, however, the number of people aged 65 and over will exceed the number of children under five. Due to declining birth rates and significant increases in life expectancy, population aging will continue, if not accelerate. According to the World Health Organization, the number of people aged 65 and over is expected to exceed 1.5 billion in 2050, with most of the increase occurring in developing countries.

Download an exclusive sample report

Where are the market opportunities?

In individual clinics and hospitals, reduced patient numbers have led doctors to embrace digital health technologies to support their businesses. When patients tried to gain safe access to outpatient care, the number of telehealth visits increased significantly. Many doctors saw an increase of 50 to 175 in the number of their telehealth visits. In a relatively short time this rise occurred, often in days or weeks at most. Health systems must create a solid, sustainable bridge that includes operational, financial, and clinical frameworks and processes, as virtual treatment is now part of the new normal. The health system will need to incorporate telehealth technologies into the electronic health record, identify clinical guidelines for effective telehealth visits, get paid for telehealth visits, and redesign hospital systems and provider practices to accommodate telehealth visits. For much of their day-to-day practices, the pandemic has increased clients’ reliance on emerging technologies. Consumers would expect their digital wellness journeys to be as productive and easy to use. During the COVID-19 situation, most of the population is dependent on digital health technology, which is expected to increase the business of prescription drugs through digital consultations. These are likely to boom the antibiotics market during the forecast period. Due to the global downturn caused by the pandemic, pharmaceutical and medical technology firms have suffered huge losses.

The competitive environment

The major players operating in the antibiotics market are Abbott Laboratories, Allergan (AbbVie Inc.), Amneal Pharmaceuticals LLC, Cipla Ltd., Cumberland Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GSK plc, Lupin, Melinta Therapeutics LLC , Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris, Inc. and WOCKHARDT. These major players operating in this market have adopted various strategies that include mergers and acquisitions, R&D investments, collaborations, partnerships, regional business expansion, and new product launches.

Recent developments

  • In November 2022, Sandoz announced an additional investment of €50 million (US$54) to support increased European production capacity for finished dosage form (FDF) penicillins, the leading antibiotic class globally. The new commitment follows plans announced last year to invest more than 100 million euros (US$108) in new manufacturing technology to produce amoxicillin oral active pharmaceutical ingredient (API) in Kundl, Austria.
  • In March 2022, AN2 Therapeutics’ IPO raised US$69 million to take an antibiotic from Pfizer into a pivotal trial. AN2 is developing an antibiotic based on boron chemistry that may offer advantages over carbon molecules.

To access the data contained in this document, please send an email [email protected]

To find more Visiongain research reports on Pharmaceuticals sector, click on the following links:

Do you have custom requirements that we can help you with? Do you need a specific country, geographic region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:[email protected]

About Visiongain

Visiongain is one of the fastest growing and most innovative independent market intelligence providers, the company publishes hundredsmarket research reports which every year adds to its extensive portfolio. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence. Visiongain operates in a number of vertical markets with many synergies. These markets include the automotive, aerospace, chemicals, cyber, defense, energy, food and beverage, materials, packaging, pharmaceutical and utilities sectors. Our custom and syndicated market research reports offer dedicated market intelligence customized to your own business needs.


Oliver Davison
Visiongain Reports Limited
Phone: +44 (0) 20 7336 6100
Email:[email protected]

Leave a Comment

Your email address will not be published. Required fields are marked *